JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
The investigation of janus kinase 2 and calreticulin mutations in patients with essential thrombocytosis
Abstract
Aims: The aims of this study were to investigate the frequency of Janus Kinase 2 (JAK2) and calreticulin (CALR) mutations in patients with essential thrombocytosis (ET) and primary myelofibrosis (PMF) and to compare the data of each group with JAK2 and CALR mutations (+) and (-).
Methods: The research group consisted of 80 patients with chronic myeloproliferative disease (CMPD) followed in Gazi University Hospital of Medical Faculty, Hematology Clinic.
Results: Of the patients included in the study, 66.2% had ET and 33.8% had PMF. JAK2 mutation (+) was detected in 60% and CALR mutation (+) was found in 22.5% of the patients. JAK2 mutation (+) was detected in 60.4% of patients with ET and 59.3% of patients with PMF. In JAK2 (-) patients, CALR was detected as (+) in 11 patients (52.4%) with ET and 7 patients (63.6%) with PMF.
Conclusion: Studies in the literature have shown that the incidence of CALR mutations in patients with CMPD is between 28% and 80% and that the mutation is mostly seen in patients with ET. As a result of our study, it was concluded that the laboratory findings of patients with CALR mutations (+) were similar to those in the literature and were more common in women and ET patients.

Keywords : Essential thrombocytosis, primary myelofibrosis, JAK2, calreticulin

Download Article


1. Dinçol G, Pekçelen Y, Atamer T, et al. Klinik Hematoloji. Nobel TıpKitabevleri; 2003;(1)238-253.
2. Yönal İ, Sargın DF. Esansiyel trombositemi: patogenez, teşhis ve tedaviningüncellenmesi. İst Tıp Fak Derg. 2014;77(1):14-20.
3. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in thepathogenesis and therapy of miyeloproliferative disorders. Nat RevCancer. 2007;7(9):673-83.
4. Kralovics R ve ark. A gain of function mutation of JAK2 inmyeloproliferative disorders. N Engl J Med. 2005;(352):1779-1790.
5. Berlin NI. Diagnosis and classification of the polycythemias. SeminHematol. 1975;(12):339-351.
6. Ruben A. Primary myelofibrosis (PMF), post polycythemia veramyelofibrosis (post-PV MF), post essential thrombocythemiamyelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensuson terminology by the international working group for myelofibrosisresearch and treatment (IWGMRT). Leukemia research. 2007;(31):737-740.
7. Lasho TL, Pardanani A, McClure RF, et al. Concurrent MPL515and JAK2V617F mutations in myelofibrosis: chronology of clonalemergence and changesin mutant allele burden over time. Br J Haematol.2006;(135):683-687.
8. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosisof essential thrombocythemia, polycythemia vera, and idiopathicmyelofibrosis (agnogenic myeloid metaplasia). Int J Hematol.2002;(76):133-145.
9. Baxter EJ, Scott LM, Campbell PJ, et al. Cancer Genome Project. Acquiredmutation of the tyrosine kinase JAK2 in human myeloproliferativedisorders. Lancet. 2005;(365):1054-1061.
10. Hsu HC. Pathogenetic role of JAK2 V617F mutation in chronicmyeloproliferative disorders. J Chin Med Assoc. 2007;(70):89-93.
11. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation ofJAK2 in myeloproliferative disorders. N Engl J Med. 2005;(17):1779-1790.
12. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutationleading to constitutive signalling causes polycythaemia vera. Nature.2005;434(7037):1144-1148.
13. Smith, MJ, Koch GL. Multiple zones in the sequence of Kalretikülin(CRP55, calregulin, HACBP), a major calcium binding ER/SR protein.EMBO Journal. 1989;(8):3581-3586
14. Waisman DM, Salimath BP. Isolation and characterization of CAB-63, anovel calcium-binding protein. J Biol Chem. 1985;(260):1652-1660.
15. Michalak M, Corbett EF. Kalretikülin: one protein, one gene, manyfunctions. Biochem J.1999;(344):281-292.
16. Tefferi A, Wassie EA, Guglielmelli P. et al. Type 1 versus Type 2calreticulin mutations in essential thrombocythemia: a collaborativestudy of 1027 patients. Am J Hematol. 2014;89(8);121-124.
17. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, TefferiA. Clinical correlates of JAK2 V617F presence or allele burdenin myeloproliferative neoplasms: a critical reappraisal. Leukemia.2008;22(7):1299-1307.
18. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospectiveidentification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia. 2007;21(9):1952-1959.
19. Panani AD. Janus kinase 2 mutations in Philadelphia negative chronicmyeloproliferative disorders: Clinical implications. Cancer Lett. 2009;284(1):7-14.
20. Wong RS, Cheng CK, Chan NP, et al. JAK2 V617F mutation is associatedwith increased risk of thrombosis in Chinese patients with essentialthrombocythaemia. Br J Haematol. 2008;141(6):902-904.
21. Demir AK, Atay MH, Kelkitli E, Kurt YT, Özatlı D, Turgut M. KronikMiyeloproliferatif Hastalıklarda JAK2V617F Mutasyon Sıklığı. ÇağdaşTıp Derg. 2013;3(2):101-107.
22. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012update on diagnosis, risk stratification, and management. Am J Hematol.2012;87(3):285-293
23. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis,myelofibrosis, and leukemia in essential thrombocythemia: a study of 605patients. Haematologica. 2008;93(11):1645-1651.
24. Lundberg P, Nienhold R, Ambrosetti A, et al. Somatic mutations inKalretikülin can be found in pedigrees with familial predisposition tomyeloproliferative neoplasms. Blood. 2014;(123):2744-2745.
25. Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations ofJAK2 , CALR, or MPL in primary myelofibrosis. Blood. 2014;(124):1062-1069.
26. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutationsof Kalretikülin in myeloproliferative neoplasms. N Engl J Med.2013;(369):2379-2390.
27. Nangalia, J, Massie C.E, Baxter EJ, et al. Somatic CALR mutations inmyeloproliferative neoplasms with nonmutated JAK2. N Engl J Med.2013;369(25):2391-2405.
28. Cabagnols X, Defour JP, Ugo V, et al. Differential association ofKalretikülin type 1 and type 2 mutations with myelofibrosis andessential thrombocytemia: relevance for disease evolution. Leukemia.2015;29(1):249-252.
Article available in :
Volume 2, Issue 3, 2024
Page : 54-58
https://doi.org/10.51271/JCHOR-0038
Article Information
Received : 12 Şub 2024
Accepted : 04 Mar 2024
Published : 01 Ağu 2024
Corresponding Author :

Servihan Ünal: Yıldırım Beyazıt University, Yenimahalle Training and Research Hospital, Department of Hematology, Ankara, Türkiye

[email protected]
Citation : Ünal S, Yağcı AM. The investigation of janus kinase 2 and calreticulin mutations in patients with essential thrombocytosis. J Curr Hematol Oncol Res. 2024;2(3):54-58.

Read: 121
Cited: 0
Download : 56
_Footer